Key Companies Covered in the Active Pharmaceutical Ingredient Market Research Report Are Teva Pharmaceutical Industries Ltd, AbbVie Inc., Abbott, Aurobindo Pharma, Cipla Inc., Dr. Reddy’s Laboratories Ltd, Sun Pharmaceutical Industries Ltd, Amgen Inc., Biocon, Mylan N.V. and other key market players.
Global active pharmaceutical ingredient market is expected to gain impetus from the increasing prevalence of infectious diseases and cancer.
It would further surge the demand for API to develop unique drugs. The National Cancer Institute estimated that in 2018, approximately 1,735,530 new cases of cancer were diagnosed. This is likely to increase up to 23.6 million by 2030. Fortune Business Insights
Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/active-pharmaceutical-ingredient-api-market-102656
This Report Answers the Following Questions:
- Which company would remain on top in the coming years?
- Which segment is expected to dominate in the near future?
- What are the challenges and opportunities in the market?
- How will companies surge sales of API amidst COVID-19 pandemic?
Drivers & Restraints-
Rising Usage of Imported API for Developing Unique Products will Aid Growth
The Indian Brand Equity Foundation (IBEF) announced that the Indian pharmaceutical industry is anticipated to exhibit a CAGR 22.4% during 2015-2020. After India, the industry in China is considered to be the second largest. As the cases of chronic diseases are increasing rapidly day by day, there is a high demand for demand and biologics across the globe. Besides, in emerging countries, the utilization of imported API is increasing to develop highly innovative biopharmaceutical products. Several pharmaceutical companies globally are focusing mainly on research and development activities development activities to unveil state-of-the-art drugs. However, the frequent and unexpected changes in drug pricing policy, especially in the developing countries of the world may hamper the active pharmaceutical ingredient market growth in the near future.
The outbreak of the COVID-19 pandemic has created huge losses for a large number of companies. Most of them have either halted their operations or have reduced their workforce to maintain social distancing. Our reports would offer elaborate data about the effects of the pandemic on every market. You can opt for the strategy applicable to intensify competition.
To get to know more about the short-term and long-term impact of COVID-19 on this market, please visit: https://www.fortunebusinessinsights.com/active-pharmaceutical-ingredient-api-market-102656
Regional Analysis-
Presence of Numerous Pharmaceutical Companies to Favor Growth in Asia Pacific
Geographically, North America procured USD 79.80 billion revenue in 2018. This growth is attributable to the increasing prevalence of chronic diseases in this region. Coupled with this, the rising government initiatives to develop innovative drugs would also contribute to the market growth here. Asia Pacific, on the other hand, is likely to outpace Europe and North America by exhibiting a high CAGR. It would mainly occur because of the increasing number of pharmaceutical companies and contract manufacturing organizations in India and China.
Quick Buy – Active Pharmaceutical Ingredient Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/102656
Competitive Landscape-
Key Players Focus on Developing New Drugs to Cure Chronic Disorders
The market houses a large number of API manufacturers, such as Mylan, Teva, AbbVie, and others. They possess a diversified product portfolio and wide networks across the globe. Most of them are nowadays focusing on developing new drugs to cure cancer and other related diseases. Below are two of the latest industry developments:
- February 2020: Sanofi declared its plans to develop a standalone organization that would be integrated with the former’s six European API production sites.
- January 2018: Pfizer partnered up with Sangamo Therapeutics, Inc. to co-develop a potential gene therapy for treating amyotrophic lateral sclerosis (ALS).
Fortune Business Insights
- Teva Pharmaceutical Industries Ltd
- AbbVie Inc.
- Abbott
- Aurobindo Pharma
- Cipla Inc.
- Reddy’s Laboratories Ltd
- Sun Pharmaceutical Industries Ltd
- Amgen Inc.
- Biocon
- Mylan N.V.
- Others
Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/active-pharmaceutical-ingredient-api-market-102656
Active Pharmaceutical Ingredient Market Segmentations:
By Type
- Generic API
- Branded API
By Synthesis
- Biological API
- Synthetic API
By Geography
- North America (U.S. and Canada)
- Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
- Asia-Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia- Pacific)
- Rest of the World
Have a Look at Related Reports:
Contract Development and Manufacturing Organization Market Size, Share & Industry Analysis, By Service {By CMO (API, Finished Product {Solid Dosage Forms, Injectables, and Others}, and Packaging)} {By CRO (Discovery, Preclinical, Clinical Trial, and Laboratory Services)} and Regional Forecast, 2019-2026.
Contract Research Organization Services Market Size, Share and Global Trend By Service Type (Discovery, Pre-Clinical, Clinical, Laboratory Services), By Application (Oncology, Cardiology, Infectious Disease, Metabolic Disorders), By End User(Pharmaceutical & Biotechnological Companies, Medical Device Companies, Academic & Research Institutes) and Geography Forecast till 2026.
About Us:
Fortune Business Insights
Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.
At Fortune Business Insights
Contact Us:
Fortune Business Insights
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune – 411045, Maharashtra, India.
Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245